Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Current Assets (2023 - 2025)

Zenas BioPharma has reported Current Assets over the past 3 years, most recently at $351.2 million for Q4 2025.

  • Quarterly results put Current Assets at $351.2 million for Q4 2025, down 1.34% from a year ago — trailing twelve months through Dec 2025 was $351.2 million (down 1.34% YoY), and the annual figure for FY2025 was $351.2 million, down 1.34%.
  • Current Assets for Q4 2025 was $351.2 million at Zenas BioPharma, up from $296.6 million in the prior quarter.
  • Over the last five years, Current Assets for ZBIO hit a ceiling of $393.8 million in Q3 2024 and a floor of $59.8 million in Q4 2023.
  • Median Current Assets over the past 3 years was $317.8 million (2025), compared with a mean of $293.4 million.
  • Biggest five-year swings in Current Assets: soared 495.15% in 2024 and later decreased 24.67% in 2025.
  • Zenas BioPharma's Current Assets stood at $59.8 million in 2023, then soared by 495.15% to $355.9 million in 2024, then fell by 1.34% to $351.2 million in 2025.
  • The last three reported values for Current Assets were $351.2 million (Q4 2025), $296.6 million (Q3 2025), and $278.6 million (Q2 2025) per Business Quant data.